Across TCGA pan-cancer cohorts, LARP4 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated LARP4 data layer compared with 24 for mass-spec protein and 6 for mass-spec protein.
The strongest signal is observed in small cell lung cancer (SCLC), where higher LARP4 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated LARP4 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.
SCLC, UCEC, and PRAD are the cancer types where LARP4 Mutation most reproducibly stratifies survival.